Medical Condition News

RSS

ADAGIO clinical trial results demonstrating AZILECT's efficacy published

Results from the ADAGIO trial, published online today in The New England Journal of Medicine, demonstrated that Parkinson’s disease patients receiving AZILECT (rasagiline) 1mg/day at the start of the study (early-start group) experienced superior benefit over 18 months compared with those who started the exact same treatment nine months later (delayed-start group).

24 Sep 2009

FDA endorses Covidien's REMS program for EXALGO tablets

Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it presented information to members of a U.S. Food and Drug Administration (FDA) Advisory Committee on the New Drug Application and proposed Risk Evaluation and Mitigation Strategy (REMS) program for EXALGOTM (hydromorphone HCl extended release) tablets, an opioid formulation.

24 Sep 2009

Two new studies test conventional wisdom about physician behavior

Two new studies test classic assumptions about doctor behavior, including whether fatigue, stress and even full moons impede their work. Meanwhile, separate reports investigate would-be physicians' behavior far from the exam room or operating table -- on Facebook, YouTube, and private blogs.

24 Sep 2009

NIH awards $2.5 million grant to University of Utah cardiologist

A pioneering model that a University of Utah cardiologist proposes as a cause of heart disease is the kind of creative thinking the National Institutes of Health (NIH) likes to see-and reward with one of its most prestigious honors, a $2.5 million 2009 Pioneer Award.

24 Sep 2009

Medivation commences patient treatment in clinical trial of MDV3100 in advanced prostate cancer

Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

24 Sep 2009

Cook Medical launches next-generation IVC filter delivery system for treating pulmonary embolism

Physicians can now navigate even the most tortuous anatomy with greater speed and safety with the next-generation inferior vena cava (IVC) filter delivery system introduced today by Cook Medical at TCT 2009. The release of the NavAlign™ delivery system marks the 20th anniversary of Cook’s first IVC filter and further advances the treatment of pulmonary embolism (PE), a life-threatening condition caused by blood clots in the lungs that affects thousands of Americans annually.

24 Sep 2009

Hope for heterotopic ossificiation

A recent United States Army study found that excessive bone growth, also known as heterotopic ossificiation (HO), affects up to 70 percent of soldiers who are severely wounded during combat. A much smaller percentage of the civilian population also suffers from HO following trauma or invasive surgery. The excessive bone forms within muscles and other tissues causing severe pain, reduced mobility and even local paralysis if untreated.

24 Sep 2009

Adolescent depression and anxiety: Two distinct psychiatric disorders

Adolescent depression and anxiety disorders are two distinct psychiatric disorders, according to Dr. William W. Hale III (a researcher of the Langeveld Institute for the Study of Education and Development in Childhood and Adolescence at Utrecht University) in a recent publication in the Journal of Child Psychology and Psychiatry.

24 Sep 2009

Also in global health news: Malawi HIV/AIDS fight; cancer in developing world

Tim Gilbo, the World Bank's director in Malawi, announced on Tuesday that the organization will grant the country $30 million, which will be used to "increase access to prevention, treatment and mitigation services with a focus on behavioural change," SAPA/News24.com reports. Gilbo also said the country should "identify and promote those programmes that are working and drop or redesign those that are not bearing any fruits." UNAIDS Malawi coordinator Desmond Johns said HIV/AIDS is "arguably the single consistent threat in overall development" for Malawi (9/22).

24 Sep 2009

Research study links high-fructose diet to increased blood pressure in men

A high-fructose diet raises blood pressure in men, while a drug used to treat gout seems to protect against the blood pressure increase, according to research reported at the American Heart Association's 63rd High Blood Pressure Research Conference.

24 Sep 2009

Researchers visualize vasculature within native liver cyst walls of human ADPKD patients

As part of an effort to develop effective medical therapies that block the progression of liver cyst growth in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD), researchers at the University of Colorado Anschutz Medical Center have found that the liver cyst walls develop and maintain a vasculature as they grow out from the body of the liver and that factors released by epithelial cells that line the liver cyst wall lumen can drive the proliferation and development of vascular endothelial cells.

24 Sep 2009

ImmunoCellular Therapeutics completes humanization of its ICT-37 and ICT-109 antibody candidates

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that it has completed humanization of ICT-37 and ICT-109.

23 Sep 2009

Oxygen Biotherapeutics to commence Phase II-b trial of Oxycyte in treating traumatic brain injury

Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has received approval from Israel's Ministry of Health to begin a Phase II-b, dose escalation, clinical trial in that country for use of Oxycyte(R) in traumatic brain injury (TBI). Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.

23 Sep 2009

The ThermoDox and MR-HIFU program shows great promise for treating life-threatening cancers

Royal Philips Electronics (NYSE: PHG; AEX: PHI) and Celsion Corporation (NASDAQ: CLSN) today announced that their joint research program to evaluate ThermoDox® in combination with MR-HIFU (Magnetic Resonance guided High Intensity Focused Ultrasound) as a combination therapy to non-invasively treat difficult cancers has successfully completed the feasibility stage.

23 Sep 2009

Results of Phase 3 CRYSTAL study of mCRC patients announced

The retrospective CRYSTAL analysis was conducted as a result of an effort to increase the tissue ascertainment rate to determine the K-ras status of patients’ tumors. The analysis included extended patient follow up of nearly 1.5 years and doubled the tissue ascertainment rate from 45% to 89%. These data are an update from the overall survival results from CRYSTAL that were published in the April 2009 issue of the New England Journal of Medicine.

23 Sep 2009

Interactive campaign to raise awareness on breast cancer

This week, Yoplait, in partnership with Susan G. Komen for the Cure, launched Know Your Girls, an interactive campaign that empowers young women to learn about breast cancer risk factors -- and then share this knowledge with their circle of friends.

23 Sep 2009

Pluristem commences dosing in Phase I clinical trial for the treatment of critical limb ischemia

Pluristem Therapeutics Inc. (NasdaqCM: PSTI; DAX: PJT) today announced the dosing of the first patient in the U.S. with its placenta-derived stem cell product, PLX-PAD, the Company’s leading candidate, in a Phase I clinical trial for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD).

23 Sep 2009

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trial showing that Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, significantly extended progression-free survival in patients with advanced breast cancer.

23 Sep 2009

New drug test promises to yield quick and effective response for cancer therapy

A group of scientists from Hamburg may have taken a big step towards more effective cancer drug development, Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], heard today (Wednesday 23 September). Dr Ilona Schonn, Director of Cell Culture Research at Indivumed GmbH, told the conference that they had developed a preclinical drug test platform that would enable researchers to analyse tumour tissue for individual patient drug responses on the molecular level.

23 Sep 2009

Improved respiratory health in Mexican women who use vented stoves

Women in Central Mexico who used a vented stove instead of the traditional indoor open fire, experienced improved respiratory health on par with a pack-a-day smoker kicking the habit, according to a recent study.

23 Sep 2009

Medical Condition News

ADAGIO clinical trial results demonstrating AZILECT's efficacy published

FDA endorses Covidien's REMS program for EXALGO tablets

Two new studies test conventional wisdom about physician behavior

NIH awards $2.5 million grant to University of Utah cardiologist

Medivation commences patient treatment in clinical trial of MDV3100 in advanced prostate cancer

Cook Medical launches next-generation IVC filter delivery system for treating pulmonary embolism

Hope for heterotopic ossificiation

Adolescent depression and anxiety: Two distinct psychiatric disorders

Also in global health news: Malawi HIV/AIDS fight; cancer in developing world

Research study links high-fructose diet to increased blood pressure in men

Researchers visualize vasculature within native liver cyst walls of human ADPKD patients

ImmunoCellular Therapeutics completes humanization of its ICT-37 and ICT-109 antibody candidates

Oxygen Biotherapeutics to commence Phase II-b trial of Oxycyte in treating traumatic brain injury

The ThermoDox and MR-HIFU program shows great promise for treating life-threatening cancers

Results of Phase 3 CRYSTAL study of mCRC patients announced

Interactive campaign to raise awareness on breast cancer

Pluristem commences dosing in Phase I clinical trial for the treatment of critical limb ischemia

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

New drug test promises to yield quick and effective response for cancer therapy

Improved respiratory health in Mexican women who use vented stoves

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News